Q1 Earnings Estimate for RAPP Issued By HC Wainwright

Rapport Therapeutics, Inc. (NASDAQ:RAPP) – HC Wainwright issued their Q1 2027 earnings estimates for Rapport Therapeutics in a note issued to investors on Wednesday, August 12th. HC Wainwright analyst D. Tsao forecasts that the company will post earnings per share of ($1.63) for the quarter. HC Wainwright currently has a “Buy” rating and a $66.00 target price on the stock. The consensus estimate for Rapport Therapeutics’ current full-year earnings is ($4.09) per share. HC Wainwright also issued estimates for Rapport Therapeutics’ Q2 2027 earnings at ($1.68) EPS, Q3 2027 earnings at ($1.73) EPS and Q4 2027 earnings at ($1.77) EPS.

A number of other research firms have also issued reports on RAPP. BTIG Research reissued a “buy” rating and set a $65.00 price target on shares of Rapport Therapeutics in a report on Wednesday, August 5th. Leerink Partners started coverage on Rapport Therapeutics in a research note on Wednesday, June 24th. They set an “outperform” rating and a $52.00 price objective for the company. Truist Financial started coverage on Rapport Therapeutics in a research report on Monday, May 18th. They set a “buy” rating and a $56.00 price objective for the company. Wall Street Zen downgraded Rapport Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, William Blair started coverage on Rapport Therapeutics in a research note on Tuesday, July 28th. They issued an “outperform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $61.57.

Rapport Therapeutics Stock Performance

NASDAQ RAPP opened at $47.36 on Friday. The firm’s fifty day moving average is $40.66 and its two-hundred day moving average is $35.20. Rapport Therapeutics has a one year low of $13.86 and a one year high of $49.50. The firm has a market cap of $2.27 billion, a PE ratio of -15.58 and a beta of 0.97.

Rapport Therapeutics (NASDAQ:RAPP) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.07).

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. TRV GP V LLC purchased a new stake in shares of Rapport Therapeutics in the 2nd quarter worth about $261,709,477,000. BlackRock Inc. purchased a new stake in shares of Rapport Therapeutics in the second quarter valued at about $112,500,000. Johnson & Johnson acquired a new stake in shares of Rapport Therapeutics in the second quarter valued at approximately $74,360,823,000. TRV GP VI LLC purchased a new position in shares of Rapport Therapeutics during the 2nd quarter worth approximately $40,387,314,000. Finally, Vestal Point Capital LP acquired a new position in shares of Rapport Therapeutics during the 3rd quarter worth approximately $28,215,000.

Insider Buying and Selling

In related news, major shareholder Rock Ventures V. L.P. Third sold 18,572 shares of Rapport Therapeutics stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $40.05, for a total transaction of $743,808.60. Following the completion of the transaction, the insider directly owned 6,280,525 shares of the company’s stock, valued at approximately $251,535,026.25. The trade was a 0.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Abraham Ceesay sold 28,958 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $48.01, for a total value of $1,390,273.58. Following the sale, the chief executive officer owned 486,108 shares in the company, valued at approximately $23,338,045.08. The trade was a 5.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 72,281 shares of company stock valued at $3,269,892. Insiders own 12.48% of the company’s stock.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.